FDA denies approval for Actavis hypertension treatment

By

Generic drug maker Actavis Plc said the U.S. health regulator denied an approval for its hypertension treatment, a fixed-dose combination of nebivolol and valsartan.

The company said it would review the U.S. Food and Drug Administration's complete response letter and decide on appropriate next steps.

The regulator issues a complete response letter when a new or generic treatment cannot be approved in its current form.

Actavis did not give any further details on the contents of the letter.

In a study, the drug combination was found more effective in reducing blood pressure in patients of hypertension, compared with independent doses of nebivolol and valsartan, Actavis said.

The company's shares closed at $254.20 on the New York Stock Exchange on Wednesday.

Tags
U.S., U.S. Food and Drug Administration
Join the Discussion
More News
Stefanie Damron

Stefanie Damron Missing: Police Intensify Search For Maine Teen 2 Months After Vanishing Near Woods

Alexandrea G. Ring

Pregnant Indiana Mother 'Threw' Her Baby Daughter After She Cried, Police Say

A Teen Girl Has Just Become the Youngest Person to Pass the California Bar Exam. The Previous Record Holder Was Her Brother

Florida Mom Accused of Drowning Daughter in Bathtub, Then Chasing

Florida Mom Accused of Drowning Daughter in Bathtub, Then Chasing Witnesses Around Apartment with a Hammer

Real Time Analytics